The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
May 6th 2024
Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.
FDA Approves Citrate-Free High-Concentration Humira Biosimilar Hadlima
August 18th 2022Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Read More
Clinical Overview: Cyletzo, a Biosimilar Version of Adalimumab
July 19th 2022Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Read More
Biosimilar Candidate to Ustekinumab Shows Positive Results Treating Plaque Psoriasis
April 20th 2022The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.
Read More